2857070-72-3

2857070-72-3 structure

Name: Anticancer agent 98
Chemical Name: Anticancer agent 98
CAS Number: 2857070-72-3
Molecular Formula: C₁₇H₁₉N₅O₂
Molecular Weight: 325.37
Catalog: Signaling Pathways Cell Cycle/DNA Damage Microtubule/Tubulin
Create Date: 2023-05-15 14:12:42
Modify Date: 2024-07-16 19:18:47
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (Kd=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t1/2>300 min[1].

Name	Anticancer agent 98

Description	Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (Kd=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t1/2>300 min[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin
In Vitro	Anticancer agent 98 抑制黑色素瘤、乳腺癌和胰腺癌的癌症增殖，IC50 范围为 0.6-3 nM[1]。 Anticancer agent 98 (300 nM、1 μM 或 3 μM；2 小时) 剂量依赖性地增加 PC-3 细胞中的 β-微管蛋白加合物[1]。 Anticancer agent 98 (3.125、6.25、12.5、25 和 50 μM) 对微管蛋白具有高结合亲和力，SPR 光谱分析的 Kd 值为 16.9 μM[1]。 Anticancer agent 98 (10 μM、50 μM；0-60 分钟) 在 60 分钟内强烈抑制微管蛋白聚合[1]。 Anticancer agent 98 (100 nM; 4 h) 在体外对 COS-7 细胞具有抗增殖和抗血管生成作用[1]。体外代谢稳定性[1] human microsomes mouse microsomes t1/2 (min) CLint (μL/min/mg) t1/2 (min) CLint (μL/min/mg) >300 <2.31 >300 <2.31
In Vivo	Anticancer agent 98 (2.5 mg/kg；静脉注射；每周两次，持续 2 周) 耐受性良好，在雄性 NSG 小鼠的 PC3/TxR 异种移植肿瘤中没有显着的体重减轻。相对于 Paclitaxel (HY-B0015；10 mg/kg，每周一次) 和对照组，Anticancer agent 98 还显着减缓了前列腺癌肿瘤的进展[1]。 NSG 小鼠中的药代动力学分析[1] Route Dose (mg/kg) Cmax (ng/mL) tmax (min) AUC (ng·min/mL) t1/2 (min) F (%) i.v. 4 1247 5.0 173,476 238 / p.o. 10 78.3 10.0 8161 358 2.02 Animal Model: PC3/TxR xenograft model in NSG mouse[1] Dosage: 2.5 mg/kg Administration: IV; twice weekly for 2 weeks Result: Inhibited the tumor growth in volume by approximately 85.6%. And inhibited angiogenesis by 44% related to control group. Overcame taxane resistance at a low, safe, but potent dose in vivo.
References	[1]. Pochampally S, et al. Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site-Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo[J]. ACS Pharmacology & Translational Science, 2023.

Molecular Formula	C₁₇H₁₉N₅O₂
Molecular Weight	325.37

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2857070-72-3	2401013-08-7
146537-05-5	2914922-83-9
2088956-21-0	2710312-73-3
38116-01-7	2332936-95-3
2470015-35-9	905783-28-0
2171886-95-4	2171880-74-1
2171237-32-2	2308463-57-0
2648912-34-7	2171708-84-0
2171233-43-3	2171428-13-8
2171428-28-5	2171163-55-4